Vir to present expanded Phase 2 SOLSTICE data on elebsiran-tobevibart combo in hepatitis delta at AASLD 2026
VIR•Vir Biotechnology plans to present expanded Phase 2 SOLSTICE data on elebsiran with tobevibart in chronic hepatitis delta at AASLD The Liver Meeting 2026, Nov. 5-9 in Denver. The update will cover efficacy through Week 96, with a separate oral presentation on a translational sub-study of intrahepatic immune-cell changes.
1. Planned data presentations
Vir Biotechnology flagged expanded Phase 2 SOLSTICE results for elebsiran with tobevibart in chronic hepatitis delta for presentation at AASLD The Liver Meeting 2026, scheduled for Nov. 5-9 in Denver. The efficacy-focused update will cover data through Week 96, while a separate oral presentation will examine intrahepatic immune-cell changes seen with the regimen.
